Leading broker names Ramsay Health Care Limited (ASX:RHC) shares as a sell

Goldman Sachs has slapped a sell rating on Ramsay Health Care Limited (ASX:RHC) shares. Here's why…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Unfortunately for its shareholders, the Ramsay Health Care Limited (ASX: RHC) share price could be spending another day in the red on Monday after it was the subject of a bearish broker note.

According to a note out of Goldman Sachs, the broker has initiated coverage on the private hospital operator with a sell rating and $49.00 price target. This target implies potential downside of over 9% for Ramsay Health Care's shares.

Why is Goldman Sachs bearish on Ramsay?

Goldman has made the move on the belief that Ramsay's shares are overvalued, especially given the challenging industry dynamics which are likely to persist through the medium term.

In respect to its valuation, the broker's sum of the parts analysis estimates that the market has valued Ramsay's Australian hospitals at a 38% premium to its global peers. Although it acknowledges that a premium is justified given the portfolio's greater scale and diversification, it doesn't believe it is deserving of such a premium.

This is partly down to the challenging industry dynamics it faces from rising healthcare costs and the decline in private health insurance (PHI) participation.

Goldman has stated that that the: "decline in PHI participation directly pressures hospital operator utilisation but furthermore, as policyholders seek exclusions to maintain affordability, the value of the remaining policies fall."

Before adding that: "We believe that regulatory attempts to address affordability through a focus on PHI premium growth risk being counter-productive long-term but certainly dilutive near-term and do not tackle the burgeoning disconnect between Medicare and Private fees which, in our view is a pertinent issue. Remedial policy is challenging to execute and we expect these pressures to persist through the mid-term."

Because of these challenges Goldman estimates that Ramsay will only be able to grow its earnings at a compound annual growth rate of 4% through to FY 2021.

Should you invest?

Considering Ramsay's shares are changing hands at approximately 20x estimated forward earnings, I would have to agree with Goldman that they are overvalued.

I've been bearish on Ramsay for some time now and this remains the case even after the sizeable drop in its share price.

Should its share price fall to around $45.00 I would be interested in making a patient long-term investment, but until then I see far better risk/rewards on offer from elsewhere in the healthcare sector with shares such as CSL Limited (ASX: CSL) and Cochlear Limited (ASX: COH).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »